Evaluating Diagnosis and Treatment of Oral and Esophageal Candidiasis in Ugandan AIDS Patients

Ravera, M.; Reggiori, A.; Agliata, Anna Maria; Rocco, R

doi:10.3201/eid0502.990214

Cited by 13 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both articles concluded that the evidence base is generally weak and more research is required. One article that did address the efficacy of miconazole in HIV-infected patients concluded that this drug was superior to nystatin suspension for controlling oral and esophageal candidiasis [22] No systemic treatments were tested in this study.…”

Section: Oral Candidiasis In Hiv-infected Patientsmentioning

confidence: 81%

Miconazole Revisited: New Evidence of Antifungal Efficacy from Laboratory and Clinical Trials

Barasch

Griffin

2008

Future Microbiol.

View full text Add to dashboard Cite

In the past 40 years imidazoles have been used extensively in medicine for their antifungal properties. All members of the azole antifungal family inhibit ergosterol biosynthesis. However, the discovery of an additional fungicidal mode of action for miconazole has drawn renewed attention to this compound. In this article we review recent evidence of mechanistic efficacy, as well as clinical trial results of miconazole in new topical formulations.

show abstract

Section: Oral Candidiasis In Hiv-infected Patientsmentioning

confidence: 81%

Miconazole Revisited: New Evidence of Antifungal Efficacy from Laboratory and Clinical Trials

Barasch

Griffin

2008

Future Microbiol.

View full text Add to dashboard Cite

show abstract

“…Thus, even if oral and oesophageal conditions alone may not be life threatening initially, these sequelae would tend to weaken patients and make it more difficult to survive other AIDS‐related complications. Second, patients may be treated for oral recurrent candidiasis with nystatin or gentian violet paint, treatments with very low cure rates for oesophageal candidiasis (Ravera et al. 1999).…”

Section: Discussionmentioning

confidence: 99%

Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi

Zachariah

Harries

Massaquoi³

et al. 2009

Tropical Med Int Health

View full text Add to dashboard Cite

Summaryobjectves To report on the cumulative proportion of deaths occurring within 3 months of starting antiretroviral treatment (ART) and to identify factors associated with such deaths, among adults at primary health centres in a rural district of Malawi.methods Retrospective cohort study: from June 2006 to April 2008, deaths occurring over a 3-month period were determined and risk factors examined.results A total of 2316 adults (706 men and 1610 women; median age 35 years) were included in the analysis and followed up for a total of 1588 person-years (PY); 277 (12%) people died, of whom 206 (74%) people died within 3 months of initiating ART (cumulative incidence: 13.0; 95% confidence interval: 11.3

show abstract

“…This may not be adequate for C. glabrata infections, where they recommend treatment with an echinocandin, unless azole-susceptibility has been demonstrated [12]. Empiric treatment of Candida esophagitis based on endoscopic findings is not an uncommon practice at this centre and may be seen at other centres as well [21]. This could lead to inadequate treatment of infection and could be selected for higher degrees of resistance.…”

Section: Discussionmentioning

confidence: 99%

Candida glabrataEsophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen?

Wilson

Delport

Ponich

2014

International Journal of Microbiology

View full text Add to dashboard Cite

Background. Candida glabrata (C. glabrata) has become a recognized pathogen in fungal esophagitis. A proportion of these isolates are azole-resistant which may have treatment implications. Variability in the prevalence of this organism exists in the limited data available. Objective. To determine the incidence of C. glabrata esophagitis in a North American hospital setting and to highlight factors that may predispose patients to this condition. Methods. Patient charts were collected from January 1, 2009 to July 30, 2011. Any charts of patients identified as having esophagitis with a positive fungal culture were reviewed for the species of Candida and the presence of factors that would predispose them to esophageal candidiasis. Results. The prevalence of Candida esophagitis based on culture was 2.2% (37 subjects). C. glabrata was the 2nd most prevalent pathogen identified (24.3% or 9 subjects). Of the C. glabrata cohort, all patients had at least one factor predisposing them to candidiasis. Conclusion. C. glabrata esophagitis makes up a large portion of the candidal esophagitis seen in hospital. C. glabrata infections were associated with at least one risk factor for candidal infection. Given its resistance to azole-based therapy, this may have treatment implications for how candidal esophagitis is approached by the clinician.

show abstract

Evaluating Diagnosis and Treatment of Oral and Esophageal Candidiasis in Ugandan AIDS Patients

Cited by 13 publications

References 14 publications

Miconazole Revisited: New Evidence of Antifungal Efficacy from Laboratory and Clinical Trials

Miconazole Revisited: New Evidence of Antifungal Efficacy from Laboratory and Clinical Trials

Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi

Candida glabrataEsophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen?

Contact Info

Product

Resources

About